Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing

NCCN guidelines recommend genetic testing for all triple-negative breast cancer (TNBC) patients aged ≤60 years. However, due to the lack of prospective information in unselected patients, these guidelines are not uniformly adopted by clinicians and insurance carriers. The aim of this study was to de...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2014-06, Vol.145 (3), p.707-714
Hauptverfasser:	Sharma, Priyanka, Klemp, Jennifer R., Kimler, Bruce F., Mahnken, Jonathan D., Geier, Larry J., Khan, Qamar J., Elia, Manana, Connor, Carol S., McGinness, Marilee K., Mammen, Joshua M. W., Wagner, Jamie L., Ward, Claire, Ranallo, Lori, Knight, Catherine J., Stecklein, Shane R., Jensen, Roy A., Fabian, Carol J., Godwin, Andrew K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over BRCA1 Protein - genetics BRCA2 Protein - genetics Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - genetics Cancer research Cancer therapies Clinical Trial Clinical trials Female Genes Genetic Predisposition to Disease Genetic screening Genetic Testing Hereditary Breast and Ovarian Cancer Syndrome - diagnosis Hereditary Breast and Ovarian Cancer Syndrome - genetics Humans Medical tests Medicine Medicine & Public Health Middle Aged Mutation Oncology Ovarian cancer Ovarian Neoplasms - diagnosis Ovarian Neoplasms - genetics Prospective Studies Registries Triple Negative Breast Neoplasms - diagnosis Triple Negative Breast Neoplasms - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!